Fundamentals · The financial statements
Research and development expense: how R&D hits profit
How R&D is expensed under US GAAP, what R&D intensity and R&D against capex show, and what Merck’s $15.8 billion of 2025 research did to its reported profit.
On this page
Research and development expense (R&D) is what a company spent in a period on finding and building new products and processes: scientists' and engineers' pay, laboratories, prototypes, clinical trials and test materials. Under US accounting rules almost all of it is charged against profit in the year it is spent.
That treatment is what makes the line worth understanding. Money spent on a factory becomes an asset and reaches the income statement slowly, over the factory's life. Money spent on a drug candidate or a chip design reaches it at once, even though the company hopes to earn from the result for a decade. For research-heavy companies, reported profit therefore understates how much is being invested, and the balance sheet leaves out what may be the most valuable things they own.
This page reads Merck's R&D for 2025, compares seven companies, works through what profit would look like if R&D were treated like a factory, and sets R&D beside capital spending.
The idea
A company can spend a dollar today in two ways. It can use it up, as it does with this month's electricity. Or it can turn it into something that will earn money in later years, such as a building. Accounting treats the first as an expense and the second as an asset that is written off gradually.
Research sits awkwardly between the two. Its purpose is clearly to earn money later. But nobody can say on the day the money is spent whether a given project will work, or what it will be worth if it does. A building can be valued and sold; a half-finished experiment cannot. Accounting standard-setters in the United States chose the cautious answer: treat research spending as an expense, because the future benefit is too uncertain to record as an asset.
The consequence is a known gap between the accounts and the economics. A company with a large, productive research budget looks less profitable and smaller in assets than it would if the same money had gone into machinery. Analysts close the gap by looking at R&D directly.
The formula
Two things stand out. Merck's research bill of $15,789 million is not far short of its net income of $18,254 million, so the decision to keep funding it is almost as big as the profit itself. And Merck spends almost four dollars on research for every dollar on property and equipment. For a drug maker, the research budget is the investment program. A reader who looks only at capital expenditures to see how much Merck is investing misses most of it.
Where the line sits
R&D is an operating expense on the income statement, below gross profit and above operating income, usually next to selling, general and administrative expense. A company that does little research may not show the line at all and may include the cost in another line. The note on significant accounting policies says what the company counts as R&D.
Nothing for a company's own research appears on the balance sheet. Research that was bought is treated differently. When one company acquires another, research projects still in progress at the target are recorded as an intangible asset at their estimated value. When a company buys or licenses an unfinished project on its own, outside the purchase of a business, US GAAP generally requires the payment to be expensed. Either way the result is uneven: the same molecule can be an asset in one company's accounts and nothing in another's, depending only on who developed it.
How it differs by business
Seven companies from their latest Form 10-K, ordered by R&D intensity. Amounts are in $ millions.
| Company | R&D | R&D ÷ revenue | Prior year | R&D ÷ capex |
|---|---|---|---|---|
| Meta | 57,372 | 28.55% | 26.67% | 0.82 |
| Intel | 13,774 | 26.06% | 31.16% | 0.94 |
| Merck | 15,789 | 24.29% | 27.95% | 3.84 |
| Microsoft | 35,562 | 10.72% | 11.53% | 0.31 |
| Nvidia | 18,497 | 8.57% | 9.90% | 3.06 |
| Tesla | 6,411 | 6.76% | 4.65% | 0.75 |
| Boeing | 3,615 | 4.04% | 5.73% | 1.23 |
Fiscal years: 2026 for Microsoft (ended June 30, 2026) and Nvidia (ended January 25, 2026), 2025 for the others.
Intensity follows how products are created. Drug makers, chip makers and software companies sell things whose cost is mostly in the design, so a large share of revenue goes back into R&D. In this table Meta, Intel and Merck each spend about a quarter. Manufacturers of cars and aircraft spend large sums in dollars, but their revenue also has to cover materials and assembly, so R&D is a small share of it.
A falling percentage is not a falling budget. Nvidia raised its R&D by 43.2%, yet its intensity fell from 9.90% to 8.57% because revenue grew faster still. Tesla's intensity rose from 4.65% to 6.76% as R&D grew 41.2%. The ratio has two moving parts, and the dollar change has to be read beside it. Intel's intensity fell from 31.16% to 26.06% with R&D down 16.8%: there the budget itself was cut.
The ratio says nothing about results. Intel spent 26.06% of revenue on R&D in 2025 and reported an operating loss of $2,214 million. Nvidia spent 8.57% and reported operating income of $130,387 million. High intensity can mean a company is investing heavily in a strong position, or that revenue has shrunk under a research budget it cannot easily reduce.
R&D against capital expenditures
The last column compares the two ways a company invests in its future. Capital expenditures buy physical assets and are capitalized. R&D buys knowledge and is expensed.
Merck and Nvidia spend more than three times as much on R&D as on capex: their investment is almost all on the income statement. Microsoft is the opposite at 0.31, with capital expenditures of $115,948 million against R&D of $35,562 million, and Meta is at 0.82. Those two companies now invest more through capex than through research, so more of their spending reaches profit later, as depreciation, instead of at once.
This matters when comparing profit between companies. Take two companies that each invest $10 billion a year. If one does it through R&D and the other through capex, the first reports the full cost this year and the second reports only this year's depreciation. Their operating margins are not measuring the same thing. Adding R&D and capex together, and comparing the total with revenue, gives a fairer view of how much each is reinvesting.
What capitalizing would change
An invented illustration shows the size of the effect. A company spends $100 a year on R&D.
- Expensed at once, as US GAAP requires: profit is cut by $100 every year.
- Capitalized and amortized over five years, as a factory would be: the first year's $100 is charged at $20 a year. Profit is cut by $20 in year one, $40 in year two as a second layer is added, and so on up to $100 from year five onward.
In the steady state the two methods give the same profit, $100 a year either way. The difference is in the early years and on the balance sheet, where the capitalizing company would carry an asset for research not yet written off.
The methods diverge again whenever the budget changes. If spending is growing, each year's amortization is based on older, smaller budgets, so the capitalized charge stays below the cash spent and profit looks higher. That is the situation of most fast-growing technology and drug companies: expensing makes them look less profitable than a capitalizing approach would. If the budget is cut, the reverse holds. Expensing shows an immediate jump in profit, while the older layers would keep being amortized under the other method.
Where it misleads
- Cutting R&D raises profit at once. Because the whole amount is an expense of the year, a cut flows straight to operating income. The cost of the cut, in products that never arrive, shows up years later. A rising margin that comes with falling R&D deserves a second look.
- Software is a partial exception. Under US GAAP (ASC 985-20), the costs of software to be sold can be capitalized once technological feasibility is reached. Companies apply this differently, and two software companies with the same spending can report different R&D expense.
- Bought research can distort a year. Payments for acquired or licensed projects may be charged to R&D in one lump. A large change in a drug maker's R&D from one year to the next can be a single transaction and not a change in the size of its laboratories.
- IFRS reporters are not directly comparable. International standards require development costs to be capitalized once certain conditions are met. A European car or drug company can show lower R&D expense and a development asset that a US peer would not.
- Definitions vary. Some companies include the pay of every engineer, including those maintaining existing products. Others define research more narrowly. Stock-based pay to research staff is inside the line.
- Spending is not output. Intensity counts dollars in. Patents granted, drugs approved and products launched are the output, and they are not on the income statement.
Compared with its neighbours
| Line or measure | What it is | Treatment in the accounts |
|---|---|---|
| R&D expense | Spending to develop new products | Expensed in the year (US GAAP) |
| Capital expenditures | Spending on property and equipment | Recorded as an asset, then depreciated |
| SG&A | Selling and running the company | Expensed in the year |
| Acquired intangibles | Patents, technology bought with a business | Recorded as an asset, then amortized or tested |
| Depreciation | Yearly write-off of past capital spending | Expense with no cash paid in the year |
R&D and advertising share the same problem: both are spending for the future that is charged against the present. Capital expenditures are the mirror image, which is why Free cash flow (FCF): definition, formula and Apple example subtracts capex but takes R&D as already deducted inside operating cash flow. The quality of earnings lesson covers other places where accounting profit and economic profit part ways.
Where to find it in Finabase
Open the income statement for Merck. The row Research and Development Expense gives the line for each fiscal year and quarter, beside Selling General and Administrative Expense, Operating Expenses and Operating Income. A row appears only when the company reports it, so a company that does not break R&D out will not have one. Selecting the row charts its full history.
Finabase has no R&D intensity row or tile. Divide the R&D row by Total Revenue for the same period. For R&D against capex, the cash flow statement has a Capital Expenditure row. On the Valuation tab, the Operating Margin tile charts ten fiscal years with a five-year median: read it knowing that the whole of each year's R&D has already been taken out.
Frequently asked questions
Is R&D capitalized or expensed?
Under US GAAP it is expensed as incurred (FASB ASC 730). The main exception is the cost of software to be sold, which can be capitalized after technological feasibility is reached (ASC 985-20). Under IFRS, research is expensed and development is capitalized once set conditions are met.
What is a good R&D to sales ratio?
It depends on the industry, so there is no single good figure. In this page's table it runs from about 4% at Boeing to about 29% at Meta. Compare a company with direct competitors and with its own past, and look at the dollar amount as well as the percentage.
Is R&D an operating expense?
Yes. It is deducted between gross profit and operating income, so operating income and every profit line below it are stated after the full year's R&D.
Why is R&D not on the balance sheet?
Because the standard treats the future benefit of a company's own research as too uncertain to record as an asset. Research acquired when buying another business is the exception: it is recorded at its estimated value at the purchase date.
Does a higher R&D budget mean higher future profit?
No. R&D is a cost of trying. Some projects produce valuable products and many produce nothing. The line shows how much a company is betting on new products, not how the bets will turn out.
Summary
Research and development expense is the cost of developing new products, and under US GAAP it is charged against profit in the year it is spent. Merck's R&D of $15,789 million in 2025 was 24.29% of revenue, 3.84 times its capital expenditures and about 43% of what its pretax income would have been before research. Intensity runs from 4.04% at Boeing to 28.55% at Meta, following how much of a product's cost lies in its design. Because the spending is expensed at once, a growing research budget makes profit look lower than it would under capitalization, and a cut makes it look higher immediately. Read the percentage with the dollar change, set R&D beside capex to see total reinvestment, and remember that the line measures effort and not results.
Check your understanding
5 questions on this lesson. Each answer comes with the reason, and nothing is scored.
A company has revenue of $400 and R&D expense of $60. What is its R&D intensity?
- 6.7%
- 24%
- 15%
Show the answer
C. 15% R&D intensity is R&D expense ÷ revenue: 60 ÷ 400 = 15%.
Under US GAAP, how is money a company spends on its own research treated?
- Expensed in the year it is spent, with no asset recorded
- Recorded as an asset and amortized over five years
- Recorded as an asset and never written off
Show the answer
A. Expensed in the year it is spent, with no asset recorded FASB ASC 730 requires research and development costs to be expensed as incurred. The main exception is software to be sold, after technological feasibility.
A company’s R&D budget grows 20% every year. Compared with a rule that capitalized R&D and amortized it over five years, what does expensing do to reported profit?
- It makes profit higher
- It makes profit lower, because the full, larger budget is charged each year instead of a charge based on older, smaller budgets
- It makes no difference in any year
Show the answer
B. It makes profit lower, because the full, larger budget is charged each year instead of a charge based on older, smaller budgets With a growing budget, amortization of past years’ smaller amounts is less than this year’s spending. Expensing charges the larger figure, so profit is lower. The two methods match only when spending is steady.
Nvidia’s R&D rose 43.2% in its latest fiscal year, while R&D as a share of revenue fell from 9.90% to 8.57%. How can both be true?
- Revenue grew faster than R&D
- The company capitalized part of its R&D
- One of the two figures must be wrong
Show the answer
A. Revenue grew faster than R&D Intensity is a ratio. If the denominator, revenue, grows faster than the numerator, the percentage falls even though the dollars spent rose sharply. Read the dollar change beside the ratio.
Company A invests $10 billion a year through R&D. Company B invests $10 billion a year through capital expenditures on assets with a ten-year life, and is in its first year of doing so. Which reports the larger cost this year?
- B, because capital expenditures are larger than research costs
- They report the same cost
- A: its $10 billion is expensed now, while B reports only the first year of depreciation
Show the answer
C. A: its $10 billion is expensed now, while B reports only the first year of depreciation R&D is expensed at once. Capex is recorded as an asset and written off over its life, so B’s income statement carries about $1 billion in the first year. Their operating margins are not measuring the same thing.
Sources and further reading
- Merck & Co., Inc. — Form 10-K for the fiscal year ended December 31, 2025, filed February 24, 2026 (SEC EDGAR)
- NVIDIA Corporation — Form 10-K for the fiscal year ended January 25, 2026, filed February 25, 2026 (SEC EDGAR)
- Meta Platforms, Inc. — Form 10-K for the fiscal year ended December 31, 2025, filed January 29, 2026 (SEC EDGAR)
- Intel Corporation — Form 10-K for the fiscal year ended December 27, 2025, filed January 23, 2026 (SEC EDGAR)
- Microsoft Corporation — Form 10-K for the fiscal year ended June 30, 2026, filed July 29, 2026 (SEC EDGAR)
- Tesla, Inc. — Form 10-K for the fiscal year ended December 31, 2025, filed January 29, 2026 (SEC EDGAR)
- The Boeing Company — Form 10-K for the fiscal year ended December 31, 2025, filed January 30, 2026 (SEC EDGAR)
- SEC EDGAR — XBRL company facts (ResearchAndDevelopmentExpense, Revenues, capital expenditures) for Merck, read November 18, 2026
- FASB Accounting Standards Codification — Topic 730, Research and Development; Subtopic 985-20, Costs of Software to Be Sold, Leased, or Marketed
